Who
Bernhardt G. Zeiher
Director
Company insider
Files Form 4 as: Director, Entrada Therapeutics; Director, Amylyx Pharmaceuticals; Director, Abeona Therapeutics.
In numbers
- Trades disclosed
- 17
- Buys
- 2
- Sells
- 0
- Bought
- $96K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 4 Apr 2023
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,372 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,372 at $0.00 | filing |
| 20 May 2026filed 21 May 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Bought | $29K5,000 at $5.86 | filing |
| 20 May 2026filed 21 May 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Bought | $29K5,000 at $5.86 | filing |
| 26 Jan 2026filed 27 Jan 2026 | ABEO Abeona TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,313 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | ABEO Abeona TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,313 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 20 Mar 2025filed 24 Mar 2025 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $37K10,000 at $3.70 | filing |
| 31 Jan 2025filed 3 Feb 2025 | ABEO Abeona TherapeuticsBiotechnology | SEC FORM 4 Code A | —36,101 at $0.00 | filing |
| 13 Aug 2024filed 14 Aug 2024 | ABEO Abeona TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,044 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,753 at $0.00 | filing |
| 14 Mar 2024filed 15 Mar 2024 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 4 Apr 2023filed 4 Apr 2023 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
News
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyTRDA · manilatimes.net · 14 Oct 2026Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)TRDA · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Bernhardt G. Zeiher; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.